Mattia Galli/LinkedIn
Sep 11, 2025, 08:32
Rivaroxaban vs Apixaban in AFib and PAD – What the Data Say
Mattia Galli, Assistant Professor at Sapienza Università di Roma, Associate Editor of European Heart Journal, shared a post on X:
”Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.”
Read more here.
Stay updated with Hemostasis Today.
-
Feb 16, 2026, 13:46A Conversation on Gene Therapy in Hemophilia B – Irish Haemophilia Society
-
Feb 16, 2026, 13:45Nathan Connell Speaks on Gender Diversity In Haemostasis Care at EAHAD 2026
-
Feb 16, 2026, 13:40David McIntosh: Concrete Performance Targets for Rare Disease Patients
-
Feb 16, 2026, 13:40Ramy Abdelnaby: Exploring The Timing of Antiplatelet Administration In Minor Stroke Post-Thrombolysis
-
Feb 16, 2026, 13:33Anne Hege Aamodt Congratulates Gisle Berg Helland on PhD Defense About Stroke Outcome MRI and ML Prediction
-
Feb 16, 2026, 13:25Rucha Patil: Delighted to Contribute to The Round Table on Integrated Care of Hemophilia and Hemoglobinopathies
-
Feb 16, 2026, 13:21Quamruz Zafar: Using the FAST Approach Saves Lives and Reduces Long Term Disability
-
Feb 16, 2026, 13:21Christopher Cannon: Factor XIa Inhibition Reduces Stroke by 26% Without Increasing Bleeding
-
Feb 16, 2026, 13:15Rishiraj Sinha: Strengthening Donor Ecosystems to Support Patient Blood Management